Goldman Sachs raised the firm’s price target on Vera Therapeutics (VERA) to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka’s Voyxact, assumptions for Vera were revised to reflect a meaningfully larger TAM and higher pricing potential for the APRIL/BAFF inhibitor class in IgAN, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target lowered to $96 from $99 at JPMorgan
- Vera Therapeutics: Reinforced Buy on Atacicept’s Leading IgAN Profile, Robust Cash Runway, and Expanded Peak Sales Potential
- Vera Therapeutics Announces Departure of Chief Legal Officer
- Vera Therapeutics director buys $250K in common stock
- Vera Therapeutics price target raised to $33 from $23 at Wedbush